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Available online 31 January 2017Film forming systems offer a number of advantages for topical and transdermal drug delivery, in partic-
ular enabling production of a supersaturated state which can greatly improve drug absorption and
bioavailability. However the suitability of individual film forming polymers to stabilise the supersatu-
rated state and optimise delivery of drugs is not well understood. This study reports the use of differential
scanning calorimetry (DSC) to measure the solubility of methylphenidate both as the free base and as the
hydrochloride salt in two polymethacrylate copolymers, Eudragit RS (EuRS) and Eudragit E (EuE) and
relates this to the ability of films formed using these polymers to deliver methylphenidate across a model
membrane. EuRS provided greater methylphenidate delivery when the drug was formulated as the free
base in comparison EuE because the lower solubility of the drug in EuRS provided a higher degree of drug
saturation in the polymeric film. In contrast EuE provided greater delivery of methylphenidate
hydrochloride as EuRS could not prevent its crystallisation from a supersaturated state.
Methylphenidate flux across the membrane could be directly related to degree of saturation of the drug
in the film formulation as estimated by the drug solubility in the individual polymers demonstrating the
importance of drug solubility in the polymer included in film forming systems for topical/transdermal
drug delivery. In addition DSC has been demonstrated to be a useful tool for determining the solubility
of drugs in polymers used in film forming systems and the approaches outlined here are likely to be use-
ful for predicting the suitability of polymers for particular drugs in film forming transdermal drug deliv-
ery systems.
 2017 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Film forming systems for topical or transdermal application
contain drug and film forming excipients along with volatile sol-
vent(s) in a formulation which typically presents as a solution or
spray. On contacting the skin, the volatile solvent evaporates leav-
ing the drug in a residual film of excipients on the skin surface.
Film forming systems offer a number of advantages over more con-
ventional formulation types; they can provide a unit dose, improve
drug delivery, be applied easily to large application areas and their
rapidly drying/absorbing nature can help to minimise transference
losses of product onto clothes or other people. As such a number of
topical, film forming pharmaceutical products have been success-
fully marketed [1].Perhaps the key advantage of film forming systems over other
topical/transdermal formulation types is their potential to improve
drug absorption into and across the skin, potentially increasing the
total amount of drug delivered and also improving bioavailability.
Drug bioavailability from dosage forms applied to the skin is typi-
cally low, such that large amounts of drug are unabsorbed, remain-
ing on the skin surface or being retained in the dosage form in the
case of transdermal patches [2,3]. Improving bioavailability so that
more drug is transferred from the dosage form into the skin may
improve therapeutic outcomes and decrease production costs as
it reduces the quantity of drug required in a dosage form for a par-
ticular dose of drug to be delivered into the body. Developing film
forming systems with improved bioavailability for drugs that are
delivered transdermally and may be abused, such as opioids (e.g.
fentanyl) or stimulants (e.g. methylphenidate), may help to assist
in the development of products that are less attractive for drug
abuse, as a result of a lower abusable drug content [4].
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use of a volatile solvent that evaporates from a formulation leaving
the drug in residual solvent or film of material date back to the
1960s [5,6]. The simplest design of these systems is a solution in
which the volatile solvent (usually ethanol or isopropanol) is the
main formulation ingredient and is a carrier for the rest of the for-
mulation. The loss of solvent from the formulation increases the
drug saturation in the residual phase of the formulation that
remains on the skin surface. This increase in drug saturation or
thermodynamic activity in the formulation produces an increased
driving force for the delivery of drug across the skin which
increases in a proportional manner with the degree of saturation
(DS) of the drug in the residual formulation. If the degree of satu-
ration of the drug in the formulation increases above the solubility
limit of the drug (above 1DS), the system becomes supersaturated
[7]. Supersaturated systems can provide proportional improve-
ments in drug delivery in relation to the degree of saturation of
the drug, however these systems are unstable and if the drug pre-
cipitates from the formulation, the potential drug delivery advan-
tages are lost [8]. Selection of suitable formulation excipients, for
example anti-nucleant polymers can delay drug crystallisation
for a sufficient period of time allowing improved drug delivery to
be achieved [9].
The dynamic nature of film forming systems makes fully under-
standing drug delivery from these formulations challenging. Not
only does the degree of drug saturation in the film change as the
volatile components evaporate, but permeation of any residual sol-
vent or penetration enhancer into the stratum corneum will also
affect the degree of drug saturation in the residual formulation.
Moreover the individual capabilities of the chemical penetration
enhancers along with their ability to work with the supersaturated
system will also influence the overall drug permeation rate [10].
Therefore developing a thorough understanding of the drug deliv-
ery behaviour of these formulations has proven difficult. Much of
the current knowledge relating to the use of anti-nucleant poly-
mers to provide stabilisation relates to systems where the super-
saturated state was produced via the cosolvent method where
the polymer concentration is relatively low, for example 1% w/w
and has a negligible effect on the drug solubility in the formulation
[11]. Previous work has been performed to understand permeation
from film forming systems considering the degree of drug satura-
tion in the solvents contained in the formulation alone [12,13].
However with film forming systems a polymer is often a main
component of the residual film formed on the skin surface and it
may have a large effect on drug saturation in the residual formula-
tion and consequent drug delivery. A clear understanding of the
effects of polymers on drug delivery from film forming systems
and the stabilisation of supersaturated films would provide key
insights into helping improve the design of such formulations.
In this study methylphenidate which is available commercially
in a transdermal patch formulation (Daytrana) has been formu-
lated in film forming, metered dose aerosol spray formulations
with two different polymethacrylate polymers, Eudragit E (EuE)
and Eudragit RS (EuRS). Detailed physical characterisation of the
interaction between methylphenidate and the polymers was per-
formed with differential scanning calorimetry (DSC) and used to
measure drug solubility in the polymers to guide interpretation
of drug release from and stabilisation of supersaturated films.2. Materials and methods
2.1. Materials
Methylphenidate hydrochloride USP (MPH-HCl) was supplied
by Macfarlan Smith (Edinburgh, UK). Dimethyl ether (DME)(99.9%) was obtained from Azkonoble (London, UK). Methanol
(MeOH), acetonitrile (ACN), triethylamine (TEA), isopropyl alcohol
(IPA), absolute ethanol (EtOH) (all HPLC grade), sodium hydroxide
(NaOH) (99%), phosphoric acid (85%), hydrochloric acid (37%),
dichloromethane (DCM) (99%), propylene glycol (PG) (99%) and
sodium chloride (NaCl) (99.5%) were all acquired from Fisher Sci-
entific (Loughborough, UK). EuE and EuRS were donated by Evonik
(Essen, Germany). Non-porous, non-reinforced silicone membrane
of 0.13 cm thickness was purchased from Bioplexus (Ventura,
USA).
2.2. Preparation of MPH-base
MPH-base was prepared by performing an acid-base extraction.
In summary, accurately weighed MPH-HCl was dissolved in deio-
nised water using a separation funnel. Sodium hydroxide (3M)
was added to the funnel to render the solution alkaline and it
was shaken for 30 s. Dichloromethane (DCM) was added to the
aqueous phase to extract the methylphenidate free base. The
DCM and aqueous phase mixture was shaken for 1 min and then
left to stand for 2 min. The clear organic phase was aliquoted into
a round bottom flask. The extraction process using DCM was
repeated twice. The organic phase (the 3 extracts of DCM) was
rotary evaporated before storing at 5 C to induce crystallisation
of MPH base. Differential scanning calorimetry (DSC) (TA Instru-
ments Q200 DSC, New Castle, USA) and infrared spectroscopy (Per-
kin Elmer Frontier FTIR, Seer Green, UK) were used to confirm the
production of MPH-base (data not shown).
2.3. Preparation of metered dose aerosol formulations
MPH-base or MPH-HCl was weighed into a Purgard canister
made of clear glass and safety coated in polypropylene. All formu-
lations contained propylene glycol, either ethanol or isopropanol as
volatile solvents and either EuE or EuRS as the film forming poly-
mer, which were added to each canister as required. The formula-
tions containing ethanol had 45.5 mg of 0.03M hydrochloric acid
added to improve drug stability. The canisters were sealed with
50 ll metered Seaquest valves and DME was pressure-filled into
the sealed glass canister using a Pamasol Laboratory Plant Filling
and Sealing Station (Willi Mader AG, Pfäffikon, Switzerland). The
metered dose aerosol formulations (MDAs) were left to mix on a
roller mixer for 24 h at room temperature to allow dissolution of
the components which was assessed visually. The composition of
the formulations used in this study are provided in Table 1.
2.4. High-performance liquid chromatography (HPLC)
Quantitative analysis of MPH was performed using HPLC with a
Hewlett-Packard Series 1050 system and a Phenomenex, KinetexTM
2.6 lm XB-C18 100 Å LC Column 100  4.6 mm. An isocratic mobile
phase of 12.5:12.5:75 ACN:MeOH:pH 3 phosphate buffer (10 mM
buffer containing 8.48 g/L NaCl and 1.3 ml/L TEA with phosphoric
acid for pH adjustment) was used. The UV detection wavelength,
flow rate and injection volume were 206 nm 0.6 ml/min and
10 ll, respectively. The retention time of methylphenidate under
these conditions was approximately 9 min. The HPLC methods
were validated for linearity, precision and accuracy according to
the current ICH guidelines [14,15]. The calibration curve produced
was linear over the concentration range 1–1000 lg/ml, with a coef-
ficient of determination (r2) of 0.9999. The limits of detection
(LOD) and quantification (LOQ) were 8.80 and 26.60 lg/ml respec-
tively. Intra- and inter-day precision (% RSD) for three standards
representative of high, medium and low drug concentrations ran-
ged from 0.12 to 0.22% and 0.16 to 0.78% respectively. Accuracy
Table 1
List of the metered dose aerosol formulation constituents and the compositions of the formulations used in this study.
Formula ID Drug content (% w/w/) Residual solvent Polymer Volatile solvent* Propellant
MPH-HCl EuE spray 1.2% MPH-HCl 3% PG 6% EuE 50% A.EtOH 39% DME
MPH-HCl EuRS spray 1.2% MPH-HCl 3% PG 6% EuRS 50% A.EtOH 39% DME
1.2% MPH-base EuE spray 1.2% MPH-base 3% PG 6% EuE 30% IPA 59.8% DME
1.2% MPH-base EuRS spray 1.2% MPH-base 3% PG 6% EuRS 30% IPA 59.8% DME
3% MPH-base EuE spray 3% MPH-base 3% PG 6% EuE 30% IPA 58% DME
6% MPH-base EuE spray 6% MPH-base 3% PG 6% EuE 30% IPA 55% DME
2% MPH-base EuRS spray 2% MPH-base 3% PG 6% EuRS 30% IPA 59% DME
3% MPH-base EuRS spray 3% MPH-base 3% PG 6% EuRS 30% IPA 58% DME
4% MPH-base EuRS spray 4% MPH-base 3% PG 6% EuRS 30% IPA 57% DME
4.5% MPH-base EuRS spray 4.5% MPH-base 3% PG 6% EuRS 30% IPA 56.5% DME
5% MPH-base EuRS spray 5% MPH-base 3% PG 6% EuRS 30% IPA 56% DME
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101.67%.2.5. Solubility studies
The solubility of MPH-base and MPH-HCl in the receiver fluid
used in the permeation studies (0.1M pH 3 phosphate buffer)
and solvents used in the formulations were determined at 32 C.
Saturated solutions were prepared by adding excess MPH into
the solvents to form a suspension and continuing to stir these for
24 h in the presence of drug particles. The saturated suspensions
were filtered (using 0.2 lm PTFE filters) to remove drug particles
and the clear solutions were diluted in mobile phase prior to anal-
ysis using HPLC to quantify the drug concentration.2.6. Drug transport studies
Measurement of MPH transport across silicone membrane was
performed using Franz cells (Soham Scientific, UK). The cells were
individually calibrated using deionised water to determine their
volume and the diameter of the cell was measure using a calliper.
Each Franz cell had an approximate receiver volume and surface
area of 3 ml and 1 cm2, respectively. Silicone membrane was cut
to fit and mounted in each diffusion cell. The donor and receiver
chambers were clamped together and sealed with Parafilm. The
receiver fluid, 0.1M pH 3 phosphate buffer was added to the recei-
ver compartment and any air bubbles trapped next to the mem-
brane were removed. A magnetic flea was added to the receiver
compartment and the Franz cell was placed on a submersible stir-
ring plate places in water bath at 37 C. This provided a membrane
temperature of 32 C which was confirmed with a probe K style
thermometer (Fisher Scientific, UK). To examine drug transport
from MDA produced drug containing films, 15 sprays of each for-
mulation were applied to each Franz cell donor chamber. Glycerol
was used as a solvent to determine the drug flux from a saturated
solution of MPH-base. This was performed by adding 0.5 ml of a
saturated suspension onto each Franz cell donor chamber to pro-
vide ‘infinite’ dose conditions over the testing period. Samples of
0.2 ml of receiver fluid were removed at 0, 0.5, 1, 2 and 3 h and
either 0.2 ml or the entire quantity of receiver fluid was removed
at 4, 6, 8 and 24 h in order to maintain sink conditions and the
samples were placed in a HPLC vial prior to analysis. Following
removal of each sample, the same volume of thermostatically equi-
librated receiver fluid was added to the receiver compartment. Sta-
tistical analyses of the permeation data was conducted using
Graphpad Prism software (version 7.0 for Windows, La Jolla,
USA). Data were checked for normality using the Shapiro-Wilks
test prior to statistical comparison with one way analysis of vari-
ance (ANOVA). Post hoc comparison between groups was per-
formed with either Tukey’s or Dunnett’s multiple comparisonstest as appropriate. Statistical significance was accepted at the
p 6 0.05 level.2.7. Differential scanning calorimetry (DSC)
A TA Instruments Q200 DSC (TA Instruments, New Castle, USA)
was used to perform all thermal analysis. Cell constant and tem-
perature calibrations were performed using n-octadecane, indium
and caffeine for a range of heating rates including 0.2, 10 and
50 C/minute. A nitrogen purge of 50 ml/min was used. For the
melting enthalpy analysis of physical mixtures of MPH with EuRS
or EuE, a heating rate of 0.2 C/min was used. Physical mixtures
were prepared by accurately weighing the required quantities of
drug and polymer and by mixing/grinding in a pestle and mortar
for 1 min. Accurate quantities were then weighed into TA standard
aluminium crimped DSC pans. Glass transition analysis was per-
formed on solvent cast films that were prepared by dispensing a
38 ll of drug and polymer solution into a pre-weighed standard
aluminium DSC pan using a calibrated Gilson pipette. The samples
were placed under vacuum for 24 h to evaporate the volatile sol-
vent and were then weighed twice over a one-hour period to
ensure solvent evaporation was complete. Ethanol was used as
the volatile solvent for MPH-HCl containing polymeric films and
isopropyl alcohol was used for those containing MPH-base. All data
analysis was performed using Universal Analysis 2000 from TA
Instruments.2.8. Determining the degree of saturation of MPH within film
formulations
The degree of saturation of the drug within the film formula-
tions was assessed using two different calculation methods. The
first method [12,16,17] is described by where RS is the amount
of residual solvent (propylene glycol) within the formulation and
SS is the saturated solubility of MPH within the residual solvent.
MPH saturated solubility within the residual solvent (PG) was
assessed using HPLC.
DS ¼ % MPHð% RS SSÞ ð1Þ
The second method (Eq. (2)) involved the replacement of the
saturated solubility values within the solvent with that of the drug
in polymer (M), where P is the amount of polymer within the
formulation.
DS ¼ % MPHð% PMÞ ð2Þ
The solubility of MPH-base in the polymers (EuE and EuRS) was
determined from the melting enthalpy analysis of physical mix-
tures using DSC as described above.
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3.1. Drug transport across silicone membrane
The 24-h drug transport data across silicone membrane of for-
mulations 1.2% MPH-HCl EuE spray, 1.2% MPH-base EuE spray
and the 1.2% MPH-base EuRS spray are shown in Fig. 1a. Drug
transport from the 1.2% MPH-HCl EuRS spray formulation across
silicone membrane was not presented as the concentrations mea-
sured were below the limit of quantification at all time points. It
was noted in contrast to the other formulations, the film formed
by the 1.2% MPH-HCl EuRS formulation rapidly became cloudy fol-
lowing application to the silicone membrane, suggesting that crys-
tallisation of the drug may have occurred in the film which would
be expected to reduce or prevent drug permeation [11]. The 1.2%
MPH-HCl EuE spray and 1.2% MPH-base EuE spray, were initially
designed to differ with regards to whether the salt or free base
form of the drug was included in the formulation. However the sol-
ubility and stability of these different forms of the drug necessi-
tated the use of different volatile solvents, with the 1.2% MPH-
HCl EuE formulation containing 50% acidified ethanol and the
1.2% MPH-base EuE spray containing 30% IPA. Statistically the
same drug transport was observed from these two formulations.0
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Fig. 1. The cumulative amount of MPH transport across silicone membrane (a) for
formulations 1.2% MPH-HCl EuE (j), 1.2% MPH-base EuE (▲), 1.2% MPH-base EuRS
(d), (n = 5–6 ± SD), ***indicates statistical difference compared to 1.2% MPH-base
EuE spray, p < 0.001; (b) The cumulative amount of MPH transport across silicone
membrane (a) for the same formulations, 1.2% MPH-HCl EuE (j), 1.2% MPH-base
EuE (▲), 1.2% MPH-base EuRS (d) plotted against the square root of time. The solid
lines show linear lines of best fit for each of the data sets for up to 60% of drug
transport from the formulations.In contrast, changing the polymer from EuE (1.2% MPH-base EuE)
to EuRS (1.2% MPH-base EuRS) significantly increased drug trans-
port from the films, indicating that the polymer included in the for-
mulation has a considerable influence on drug transport. The
saturated solubilities of MPH-HCl and MPH-base in the receiver
fluid used were 152.8 and 7.0 mg/ml respectively and in order to
ensure sink conditions were maintained throughout the experi-
ment, whereby the drug concentration in the receiver fluid did
not exceed 10% of its saturated solubility, all of the receiver fluid
was removed from the Franz cells where necessary and replaced
with fresh receiver fluid. The drug transport profiles of the three
formulations shown in Fig. 1a are similar in that they initially show
rapid drug transport that gradually decreases over time. The plot of
this data against the square root of time is shown in Fig. 1b where
it can be seen that the data is linear over the initial time points
which account for approximately 60% of MPH transport from the
formulations. Such behaviour is consistent with the Higuchi model
of drug release [18]. The 1.2%, 3% and 6% MPH-base EuE formula-
tions showed proportional increases in the drug transport with
drug concentration (Fig. 2a). In contrast the formulations contain-
ing different concentrations of MPH-base with EuRS (1.2%, 2%,
3%, 4%, 4.5% and 5% MPH-base EuRS sprays), drug transport was
observed to increase with increasing the drug concentration up
to 4.5% drug loading (Fig. 2b). Further increasing the MPH-base
concentration to 5% significantly reduced drug transport compared
to that obtained with formulations containing either 4% or 4.5%
drug loading. This coincided with a visual observation of the film
produced by the 5% MPH-base formulation rapidly becoming
cloudy, suggesting that the drug may have crystallised in the film.
The formulations containing 3% or more MPH-base with EuRS, all
showed some signs of cloudiness after 24 h, which as mentioned
suggests drug crystallisation within the film. In contrast, the for-
mulations up to 6% of MPH-base with EuE all appeared visually
clear throughout the 24-h experiment.
The drug flux from a saturated solution of MPH-base in glycerol
across silicone over 24 h is shown in Fig. 2c and was used as a stan-
dard to compare with the performance of the film forming formu-
lations. The steady state drug flux from saturated solution of MPH-
base in glycerol across the 24 h period was 207 ± 54 lg/cm2/h
(Table 2). For all film forming formulations containing MPH-base,
the drug flux between 1 and 4 h were statistically greater than this
value except 1.2% MPH-base EuE and 3% MPH-base EuE. Table 2
also provides the total drug transport after 24 h of all MPH base
formulations with EuE (Fig. 2a) and EuRS (Fig. 2b) after 24 h. It is
clear that both the polymer used and drug loading can have signif-
icant impacts on the efficiency of MPH transport from the film. For
example formulations containing EuRS provided greater drug
transport than those containing EuE and mostly there was an
increase drug transport with increasing drug loading with the
exception of the 5% MPH-base EuRS formulation for which drug
transport was less than that of the 4.5% MPH-base EuRS formula-
tion. The same data was used to calculate the percentage of the
dose applied to the Franz cell that was transported across the sili-
cone membrane. As expected significantly higher values were
obtained for the EuRS containing formulations indicating that they
are more efficient at delivering the drug across the membrane.
3.2. Measurement of the solid state solubility of drug in film forming
polymers
Measurement of the drug solubility and the degree of saturation
in polymeric films that is representative of what is formed on the
skin surface is not trivial, as the volatile and residual solvent levels
in the film will change over time. However measuring the drug sol-
ubility in the polymer alone may provide useful insight into the
drug transport data interpretation. One approach to measure the
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Fig. 2. The cumulative amount of MPH transport across silicone membrane (a) for
formulations 1.2% MPH-base EuE (j) 3% MPH-base EuE (D), 6% MPH-base EuE (s);
(b) for formulations 1.2% MPH-base EuRS (d), 2% MPH-base EuRS (h), 3% MPH-base
EuRS (▲), 4% MPH-base EuRS (), 4.5% MPH-base EuRS (r) and 5% MPH-base EuRS
(s) (n = 5–6 ± SD) ***indicates statistical difference compared to 4.5% MPH-base
EuRS spray, p < 0.001; and (c) from a saturated solution of MPH-base in glycerol
(n = 6 ± SD).
Table 2
Average drug flux between 1 and 4 h across silicone membrane, the total amount of
drug transported after 24 h and the percentage of the applied dose transported across
the membrane from metered dose aerosol formulations containing MPH-base and a
saturated solution of MPH-base in glycerol. Data are presented as the mean ± SD
(n = 5–6).
Formulation Drug Flux
between 1 and
4 h (lg/cm2/h)
Total amount of
drug transported
after 24 h (mg)
Percentage of the
applied dose
transported at 24 h
(%)
Saturated
solution of
MPH base in
glycerol
207 ± 54 4.828 ± 4.32 ND
1.2% MPH-base
EuE spray
151 ± 66 1.130 ± 0.3 27.3 ± 7.3
3% MPH-base
EuE spray
429 ± 143 3.410 ± 0.72 24.1 ± 8.5
6% MPH-base
EuE spray
782 ± 173*** 5.997 ± 0.29 29.0 ± 3.5
1.2% MPH-base
EuRS spray
473 ± 93** 2.642 ± 0.62 63.8 ± 14.8
2% MPH-base
EuRS spray
887 ± 142*** 5.219 ± 1.16 75.7 ± 16.2
3% MPH-base
EuRS spray
801 ± 215*** 6.786 ± 0.90 65.6 ± 8.7
4% MPH-base
EuRS spray
1413 ± 56*** 10.301 ± 0.45 74.7 ± 3.3
4.5% MPH-base
EuRS spray
1652 ± 242*** 11.102 ± 1.09 71.5 ± 7.0
5% MPH-base
EuRS spray
941 ± 95*** 8.229 ± 1.03 47.7 ± 6.0
*Indicates statistical difference in comparison to drug transport from the saturated
solution of MPH-base in glycerol.
** p < 0.01.
*** p < 0.001.
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enthalpy of the crystalline drug (measured by DSC) when at differ-
ent weight fractions with respect to the polymer [19]. When the
drug is physically mixed with another substance such as an amor-
phous polymer that it can interact with, there is a decrease in the
observed melting enthalpy as the physical mixture is heatedthrough the drug melting temperature. This occurs because the
drug dissolves in the glassy polymer as it melts, resulting in a
reduction in the observed melting enthalpy. This reduction should
be proportional to the weight fraction of the drug in a linear man-
ner. When the weight fraction of drug is increased above the max-
imum solubility within the polymer, the linearity of the change in
enthalpy changes as the drug no longer dissolves in the polymer.
The drug fraction at this point can therefore provide a measure-
ment of drug solubility in the polymer.
The melting enthalpy of the drug within physical mixtures of
varied MPH-base content in EuE or EuRS was measured, with the
DSC curves being shown in Fig. 3. Two features can be clearly seen
in Fig. 3. Firstly, the DSC results of the physical mixtures containing
EuE show more profound melting point depression of crystalline
MPH-base in comparison to the physical mixes with EuRS. Sec-
ondly, the change of MPH-base melting enthalpy is greater in the
presence of EuE then EuRS. Both of these are indications of a higher
solubility of MPH-base in EuE than EuRS [20].
The measured enthalpy values for both EuE and EuRS physical
mixes were plotted against the drug content and are shown in
Fig. 4. For the systems containing EuE, the increase in melting
enthalpy with drug loading can be observed to occur in two linear
stages with the first occurring between 25 and 40% drug loading,
with the second from 40 to 70% drug loading (Fig. 4). According
to the methodology explained previously, the solubility of MPH-
base in EuE can be estimated from the change in gradient of the
plot which was determined using linear regression analysis to be
38% w/w. Similarly, two separate linear regions between 3 and
10% drug loading, and 10 and 65% drug loading can be observed
in the data from the melting enthalpies of the physical mixes of
MPH-base and EuRS (Fig. 4). The drug solubility within the poly-
mer was measured to be 12% w/w MPH-base in EuRS from the
change in the linearity of the plot. This analysis confirmed and pro-
Fig. 3. Representative DSC curves showing the MPH-base melting transition for physical mixtures of varying proportions of MPH-base with (a) EuE and (b) EuRS.
Fig. 4. The melting enthalpy curve for physical mixtures of varying proportions of
MPH-base with EuE (j) and EuRS (▲) (n = 3, error bars represent the range).
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solubility of MPH-base with EuE than EuRS made through melting
point depression observations.
For comparative purposes, analysis of the glass transition tem-
peratures (Tg) of solvent cast films containing different ratios of
drug and polymer was performed. Tgs have been traditionally used
to provide indication of phase separation in drug-polymer solid
dispersions [21]. If the drug is molecularly dispersed in the poly-
mer, a single Tg that changes with the proportion of drug and poly-
mer and can be predicted by the Gordon-Taylor relationship is
expected [22]. DSC data showing the Tgs of solvent cast films con-
taining different proportions of MPH-base and EuRS are presented
in Fig. 5. With incorporation of MPH-base, the Tg of the cast films
reduced. The change in Tg with drug content is plotted in Fig. 4a.
Initially, it can be seen that increasing the drug loading lowered
the Tg of the film in a concentration dependent manner up to a
drug loading of 12%. After this point the Tg of the cast films
remained relatively constant, indicating the saturation of drug
Fig. 5. (a) Representative DSC curves for solvent cast film solid dispersions of varying proportions of MPH-base with EuRS and (b) the glass transition temperatures for these
films plotted against drug loading (n = 3, error bars represent the range).
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viding a measurement of the solubility of MPH-base in EuRS. This
good agreement between the solubility values calculated by the
separate glass transition and melting enthalpy methods supports
the reliability of these methods for the measurement of solubility
of drugs in polymeric films.
As MPH-HCl undergoes melt decomposition, it was not possible
to determine the solubility of MPH-HCl within EuRS or EuE using
the melting enthalpy methodology. Therefore the glass transition
analysis method was used alone for determining the solubility of
MPH-HCl within the polymers. In the absence of drug a Tg at
approximately 46 C was observed for the Eudragit EuE film. As
the drug content was increased up to approximately 8% drug load-
ing the Tg reduced to approximately 36 C, with no further reduc-
tion being observed for the films tested containing higher
concentrations of MPH-HCl. Linear regression analysis of this data
allowed estimation the solubility of MPH-HCl with EuE to be 9% w/
w (Fig. 6). In contrast no change in the Tg of EuRS could be obtained
when MPH-HCl was included in films formed with this polymer
and visible signs drug crystallisation were observed even in films
with low drug content.3.3. Prediction of drug flux using degree of saturation measured drug
solubility in polymer
Drug flux across membranes for topical formulations is typically
directly proportional to the degree of saturation of the drug within
the delivery vehicle, if the formulation constituents do not alter the
properties of the membrane [23]. In an attempt to ascertain
whether the drug solubility in the residual solvent or in the poly-
mer had a greater effect in terms of determining the saturation
of the drug in the film, the drug flux from the MPH-base formula-
tions were plotted against the degree of drug saturation calculated
using the drug solubility in the residual solvent using Eq. (1)
(Fig. 7) or in the polymer using Eq. (2) (Fig. 8). As seen in Fig. 7,
a linear correlation was observed between the average drug flux
between 1 and 4 h from the film forming formulations containing
EuE and the degree of saturation calculated using the solubility of
the drug in PG. A separate correlation with reduced linearity was
observed for the formulations that contained EuRS. This reduced
linearity for the data produced from formulations containing EuRS,
was observed regardless of whether the data from the 5% MPH-
base EuRS formulation (6.25 DS), which appeared to have drug
Fig. 6. (a) Representative DSC curves for solvent cast film solid dispersions of varying proportions of MPH-HCl with EuE and (b) the glass transition temperatures for these
films plotted against drug loading (n = 3, error bars represent the range).
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was included.
Fig. 8a shows the correlation between the drug flux obtained
from films between 1 and 4 h following application of the formula-
tions containing EuE and EuRS and the degree of drug saturation in
the film calculated using the solubility of the drug in the polymer.
The formulations containing both EuE and EuRS fitted upon the
same line of best fit up until the EuRS formulation containing 5%
MPH-base. The decrease in drug flux for the formulation containing
5% MPH-base, as discussed previously, is likely to be a result of sig-
nificant crystallisation of the drug in the formed film. The drug
transport data in Figs. 1a and 2a, b showed that for all formulations
containing MPH base that drug flux was high over the first four
hours following application, but reduced between 6 and 24 h. In
order to determine whether a similar correlation existed for the
drug flux data between 6 and 24 h as for that between 1 and 4 h,
the average flux data between 6 and 24 h for the MPH-base formu-
lations was plotted against the degree of saturation of the drug in
the films as calculated from the solubility of the drug in the poly-mer (Fig. 8b). Although the magnitude of the drug flux was reduced
between 6 and 24 h a very similar correlation was observed to the
drug flux data produced between 1 and 4 h, with the drug flux from
both EuE and EuRS formulations following a linear correlation with
respect to the degree of drug saturation in the formulation up to
the 6.25DS produced by the 5% MPH-base EuRS formulation.
4. Discussion
The focus of this study was to develop approaches that would
help identify selection of polymers for inclusion in film forming
systems for topical and transdermal drug delivery. This would help
rationalise the development process and provide understanding of
how to optimise drug delivery from these formulations. The
metered dose aerosol produced films used in this study exhibited
drug transport data that was linear when plotted against the
square root of time consistent with Fickian diffusion as described
through the Higuchi model of drug release. This type of drug trans-
port profile is expected for drug containing topical films, including
Fig. 7. MPH flux between 1 and 4 h plotted against the degree of saturation as
calculated from the MPH-base saturated solubility within PG for MedSpray
formulations containing varied quantities MPH-base containing 3% PG, 30% IPA,
DME and either 6% EuE (j) or 6% EuRS (s) (n = 5–6 ± SD).
Fig. 8. MPH flux between (a) 1 and 4 h and (b) 6 and 24 h plotted against the degree
of saturation as calculated from the MPH-base solubility within EuRS (s) or EuE (j)
for formulations of varied MPH-base content containing 3% PG, 6% EuRS or EuE, 30%
IPA and DME (n = 5–6 ± SD).
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uration in a formulation is a key for understanding drug delivery
into and across the skin and is difficult to assess with film forming
systems given their solid nature and that the degree of saturation
changes with time in response to evaporation of solvents and thepermeation of solvents and drug into the skin. One approach to
try to understand the degree of saturation is to consider the solu-
bility of the drug in the solvents alone and how the drug saturation
in the formulation is expected to change with solvent evaporation
[12]. It has been observed however that the polymer included in a
film forming formulation can have a significant influence of the
delivery of drugs from the films, with the authors typically postu-
lating that the polymer will influence the degree of drug saturation
in the film and therefore the ‘driving force’ of the drug from the for-
mulation [25,26]. Similar results were obtained in this study with
the polymer included in the formulation being observed to have a
substantial effect on drug transport from the formulation, with dif-
ferent polymers offering improved drug transport depending on
whether the drug was in the free base or salt form. These data sug-
gest strongly that the polymer has a significant role in determining
the degree of saturation of the drug in the formed film and the
resultant flux as these large polymer molecules are unlikely to be
able to modify drug transport by other means, for example through
acting as a chemical penetration enhancer [27].
Therefore measuring drug-polymer solubility will be useful in
designing and understanding the behaviour of these dosage forms.
Assessment of drug solubility within polymeric matrices has been
investigated at some length for the development of drug contain-
ing solid dispersions for oral drug delivery with DSC being com-
monly used as a supporting tool for measurement of drug
polymer solubility and assistance of polymer selection [20]. Differ-
ent methodologies using DSC to measure drug-polymer solubility
were employed here. The melting enthalpy method is relatively
simple and does not require the production of drug containing
films, however this approach was not suitable for MPH-HCl which
decomposes as it melts; instead glass transition analysis of solvent
cast films was used. When MPH-base solubility was assessed using
the glass transition method, good agreement was found between
the solubility values supporting the use of either methodology to
measure drug-polymer solubility.
Using these methodologies marked differences in the solubility
of MPH-base in EuRS and EuE were observed, with the drug solu-
bility in EuE being considerably higher than EuRS. In addition the
solubility of MPH-HCl is likely to be considerably higher in EuE
than in EuRS, as no change in the Tg of EuRS could be obtained
when MPH-HCl was included in the film and visible signs drug
crystallisation were observed in the formed films even with low
drug content. EuE (Poly[butyl methacrylate-co-[2- demethy-
laminoeethyl] methacrylate-co-methyl methacrylate] 1:2:1) is
more hydrophilic than EuRS (Poly[ethyl acrylate-co-methyl metha
crylate-co-trimethylammonioethyl methacrylate chloride]
1:2:0.1), which may explain the improved solubility of methylphe-
nidate, particularly MPH-HCl in EuE.
In this study, DSC has been used to measure drug polymer sol-
ubility to provide understanding of the delivery of methylpheni-
date from polymeric films assessed from transport studies across
silicone membrane. Silicone membrane is commonly adopted as
a surrogate model for skin for these sorts of studies investigating
drug saturation on formulation performance [12,28,29]. Drug
transport from the film forming systems has also been compared
with that of saturated solution of MPH base in glycerol. If the sol-
vents used in a formulation vehicle do not interact with the mem-
brane to which they are applied, then drug transport rate from
different formulations that are saturated with drug should be con-
stant, allowing the DS of the film forming systems to be inferred
[23]. Glycerol was chosen for this comparison because of the rea-
sonable solubility of MPH base (16.8 mg/ml) within it. The solubil-
ity of MPH-base in propylene glycol or IPA, solvents used in the
film forming formulations were very high, 309.4 mg/ml
and > 400 mg/ml respectively making it unsuitable to perform infi-
nite dose, drug transport studies using these solvents. When com-
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film forming systems with that of the saturated solution in glyc-
erol, it would appear that most of the film forming systems are
supersaturated. This is supported by the observation that several
of the films developed small regions of crystallisation following
application to the membrane by the end of 24 four testing period.
The increased degree of supersaturation from formulations con-
taining MPH-base and EuRS in comparison to those containing
EuE relates to the lower solubility of the drug in EuRS. This agrees
with previous literature that has suggested that polymers can
increase drug solubility in a formulation which would be expected
to decrease drug flux through reducing the DS of the drug in the
vehicle [30,31]. A related example from the literature examined
the effect of polymethylmethacylates as crystallisation inhibitors
in ibuprofen containing polydimethylsiloxane/silicate drug in
adhesive patches, where inclusion of EuE instead of Eudragit RL
(a Eudragit polymer with a similar structure EuRS, containing
twice the quantity of the quaternary amine group), reduced drug
flux from the formulation and could be ascribed to the higher sol-
ubility and thus lower saturation of the drug in the EuE [32].
The drug transport from the formulations showed similar pro-
files of relatively rapid transport up to 4 h following dosing that
then slowed over 6–24 h. When the drug transport data for MPH
base was considered in relation to its solubility in the residual sol-
vent, propylene glycol, separate trends in the data were observable
only within formulations containing the same polymer. In contrast
when the drug transport data was considered in light of the solu-
bility of the polymer a single trend was observed in the data across
both polymers, up until crystallisation was observed occurring
soon after application of the formulations with the highest degree
of saturation. This trend was observable across the data of the two
polymers regardless of whether the drug flux between 1and 4 h or
6 and 24 h and supports the consideration that drug solubility in
the polymer is the key influence on drug saturation in the formed
film.
As well as increasing drug flux from the formulation, supersat-
urated systems should be able to deliver a greater proportion of the
drug included in the formulation. This is because as the drug con-
tent in the formulation decreases as the drug diffuses from the for-
mulation following administration, a higher level of drug
saturation in the formulation is maintained for longer compared
to subsaturated systems, resulting in a greater proportion of the
formulations drug content being delivered. When EuRS is used as
the polymer equivalent drug delivery after 24 h was obtained from
the 1.2% MPH base in EuRS as with 3% MPH base in EuE, which cor-
relates well with the lower solubility of MPH base in EuRS (12% w/
w) compared to EuE (38% w/w) providing two-three times more
drug transport. This highlights the importance of the drug solubil-
ity in the polymer providing a high thermodynamic driving force of
the drug within the film formulation. This has important applica-
tions as it may be able to help reduce manufacturing costs. In addi-
tion it may also be of benefit for transdermally administered drugs
such as methylphenidate that can be abused through extracting
the drug from the dosage form. This is the case as more efficient
formulations will deliver a greater percentage of the applied dose
thereby requiring a lower quantity of drug in the dosage form to
achieve the same therapeutic benefit. This will reduce the potency
of any extracts made from the product, something which will con-
tribute to lowering the abuse potential of the dosage form [4].
As supersaturated systems are unstable and will eventually
crystallise, polymers used in these formulations are often selected
to act as anti-nucleants, delaying/retarding the crystallisation pro-
cess until the drug has been delivered. The anti-nucleation effect is
not well understood, and it is known that different polymers have
different capabilities to stabilise supersaturated systems of differ-
ent drugs. For example polyvinyl pyrollidone (PVP) was found tobe superior to hydroxypropyl cellulose (HPC) in stabilising super-
saturated systems of oestradiol, whereas PVP was not able to sta-
bilise hydrocortisone acetate to the same level of supersaturation
as HPC [9,16]. The anti-nucleant polymers have been shown to
delay crystal nucleation, slow drug crystal growth and alter crystal
shape [33,34]. Interactions between the polymer and the drug
crystal face, often hydrogen bonding are considered to be impor-
tant for the anti-nucleant action [33]. These anti-nucleant studies
have been typically carried out in systems such as supersaturated
cosolvent systems where the polymer concentration is low. In the
polymeric films produced by film forming formulations, the poly-
mer concentration is relatively high and the types of interactions
such as hydrogen bonding that can contribute to an anti-
nucleant action will also provide good drug solubility restricting
the level of supersaturation that can be achieved. This may explain
why when DSC has been used previously to help aid selection of
polymers as anti-nucleants for supersaturated film forming sys-
tems, it appeared not to be useful [35].
There may be other features of the films formed from the differ-
ent polymers which may ultimately influence drug transport from
them. For example they may exhibit different occlusive effects,
which may alter the skin’s barrier properties and affect drug deliv-
ery [36]. In addition uptake of water into polymeric films as a
result of transepidermal water loss on skin or across silicone mem-
brane mounted on Franz cells may alter interactions between the
drug and the polymer within the film, something that would be
expected to be related to the hygroscopicity of the polymer and
may impact drug delivery [37]. Nonetheless the analysis presented
here relating the delivery of MPH from the films to its solubility in
the different polymers seems the most suitable explanation of the
observed drug transport behaviour. This analysis also provides an
explanation for the reduced transport of MPH-HCl from formula-
tions containing EuRS, in comparison to those containing EuE.
Although it is usually considered preferable for topical/transder-
mal drug delivery to have the drug in an unionised form in a for-
mulation in order to show improved permeation across
hydrophobic membranes such as the stratum corneum, in some
cases the improved solubility of the ionised form may outweigh
this and so it is appropriate to consider delivery of the salt form
[38]. In this study MPH-HCl could not be delivered from formula-
tions containing EuRS which is likely to be a result of the inability
of this polymer to provide suitable anti-nucleant action allowing
rapid drug crystallisation to occur which would prevent/reduce
its transport across the silicone membrane [11]. In contrast deliv-
ery of MPH-HCl could be achieved when the more hydrophilic
EuE was used, in which the drug was found to have a measurable
level of solubility. Therefore polymer selection during formulation
development for film forming systems should be based on a careful
consideration of the solubility of the drug in polymers used so that
a sufficient anti-nucleation action can be obtained without pre-
venting a high degree of drug saturation in the film from being
achieved.Acknowledgements
We would like to thank Medpharm Ltd for funding this work.References
[1] W.J. McAuley, F. Caserta, Film forming and heated systems, in: R.F. Donnelly, R.
Singh (Eds.), Novel Delivery Systems for Transdermal and Intradermal Drug
Delivery, Wiley, Chichester, 2015, pp. 97–124.
[2] S. Wiedersberg, C.S. Leopold, R.H. Guy, Bioavailability and bioequivalence of
topical glucocorticoids, Eur. J. Pharm. Biopharm. 68 (2008) 453–466.
[3] K.A. Marquardt, R.S. Tharratt, N.A. Musallam, Fentanyl remaining in a
transdermal system following 3 days of continuous use, Ann. Pharmacother.
29 (1995) 969–971.
174 A. Edwards et al. / European Journal of Pharmaceutics and Biopharmaceutics 114 (2017) 164–174[4] N.P. Katz, D.C. Buse, S.H. Budman, S.W. Venuti, K.C. Fernandez, C. Benoit, R.
Bianchi, D. Cooper, D.R. Jasinski, D.E. Smith, S.F. Butler, Development and
preliminary experience with an ease of extractability rating system for
prescription opioids, Drug Dev. Ind. Pharm. 32 (2006) 727–746.
[5] M.F. Coldman, B.J. Poulsen, T. Higuchi, Enhancement of percutaneous
absorption by the use of volatile: nonvolatile systems as vehicles, J. Pharm.
Sci. 58 (1969) 1098–1102.
[6] R.J. Feldman, H.I. Maibach, Percutaneous penetration of 14C hydrocortisone in
man. II. Effect of certain bases and pretreatments, Arch. Dermatol. 94 (1966)
649–651.
[7] A.F. Davis, J. Hadgraft, Effect of supersaturation on membrane transport: 1.
Hydrocortisone acetate, Int. J. Pharm. 76 (1991) 1–8.
[8] M.A. Pellett, S. Castellano, J. Hadgraft, A.F. Davis, The penetration of
supersaturated solutions of piroxicam across silicone membranes and
human skin in vitro, J. Control. Release 46 (1997) 205–214.
[9] S.L. Raghavan, B. Kiepfer, A.F. Davis, S.G. Kazarian, J. Hadgraft, Membrane
transport of hydrocortisone acetate from supersaturated solutions; the role of
polymers, Int. J. Pharm. 221 (2001) 95–105.
[10] P. Santos, A.C. Watkinson, J. Hadgraft, M.E. Lane, Influence of penetration
enhancer on drug permeation from volatile formulations, Int. J. Pharm. 439
(2012) 260–268.
[11] S.L. Raghavan, A. Trividic, A.F. Davis, J. Hadgraft, Crystallization of
hydrocortisone acetate: influence of polymers, Int. J. Pharm. 212 (2001)
213–221.
[12] S.A. Jones, M.L. Reid, M.B. Brown, Determining degree of saturation after
application of transiently supersaturated metered dose aerosols for topical
delivery of corticosteroids, J. Pharm. Sci. 98 (2009) 543–554.
[13] M.L. Reid, S.A. Jones, M.B. Brown, Transient drug supersaturation kinetics of
beclomethasone dipropionate in rapidly drying films, Int. J. Pharm. 371 (2009)
114–119.
[14] Q2A, Text on validation of analytical procedures: definitions and terminology,
in: Proceedings of the International Conference on Harmonization (ICH), US
FDA Federal Register, 1995.
[15] Q2B, Validation of analytical procedures: methodology, in: Proceedings of the
International Conference on Harmonization (ICH) US FDA Federal Register,
1997.
[16] N.A. Megrab, A.C. Williams, B.W. Barry, Estradiol permeation through human
skin and silastic membrane - effects of propylene-glycol and supersaturation,
J. Control. Release 36 (1995) 277–294.
[17] S.L. Raghavan, A. Trividic, A.F. Davis, J. Hadgraft, Effect of cellulose polymers on
supersaturation and in vitro membrane transport of hydrocortisone acetate,
Int. J. Pharm. 193 (2000) 231–237.
[18] T. Higuchi, Physical chemical analysis of percutaneous absorption process
from creams and ointments, J. Soc. Cosmet. Chem. 11 (1961) 85–97.
[19] S. Qi, P. Belton, K. Nollenberger, N. Clayden, M. Reading, D.Q.M. Craig,
Characterisation and prediction of phase separation in hot-melt extruded solid
dispersions: a thermal, microscopic and NMR relaxometry study, Pharm. Res.-
Dordr. 27 (2010) 1869–1883.
[20] P.J. Marsac, S.L. Shamblin, L.S. Taylor, Theoretical and practical approaches for
prediction of drug-polymer miscibility and solubility, Pharm. Res. 23 (2006)
2417–2426.[21] Q. Lu, G. Zografi, Phase behavior of binary and ternary amorphous mixtures
containing indomethacin, citric acid, and PVP, Pharm. Res. 15 (1998) 1202–
1206.
[22] M. Gordon, J. Taylor, Ideal copolymers and the second-order transitions of
synthetic rubbers. i. Non-crystalline copolymers, J. Appl. Chem. 2 (1952) 493–
500.
[23] J.N. Twist, J.L. Zatz, Influence of solvents on paraben permeation through
idealized skin model membranes, J. Soc. Cosmet. Chem. Jpn. 37 (1986) 429–
444.
[24] Y.N. Kalia, R.H. Guy, Modeling transdermal drug release, Adv. Drug. Deliv. Rev.
48 (2001) 159–172.
[25] K. Frederiksen, R.H. Guy, K. Petersson, Formulation considerations in the
design of topical, polymeric film-forming systems for sustained drug delivery
to the skin, Eur. J. Pharm. Biopharm. 91 (2015) 9–15.
[26] I. Zurdo Schroeder, P. Franke, U.F. Schaefer, C.M. Lehr, Delivery of
ethinylestradiol from film forming polymeric solutions across human
epidermis in vitro and in vivo in pigs, J. Control. Release 118 (2007) 196–203.
[27] A.C. Williams, B.W. Barry, Penetration enhancers, Adv. Drug Deliv. Rev. 56
(2004) 603–618.
[28] P. Santos, A.C. Watkinson, J. Hadgraft, M.E. Lane, Enhanced permeation of
fentanyl from supersaturated solutions in a model membrane, Int. J. Pharm.
407 (2011) 72–77.
[29] K. Moser, K. Kriwet, C. Froehlich, A. Naik, Y.N. Kalia, R.H. Guy, Permeation
enhancement of a highly lipophilic drug using supersaturated systems, J.
Pharm. Sci. 90 (2001) 607–616.
[30] S. Raghavan, B. Kiepfer, A. Davis, S. Kazarian, J. Hadgraft, Membrane transport
of hydrocortisone acetate from supersaturated solutions; the role of polymers,
Int. J. Pharm. 221 (2001) 95–105.
[31] N. Rodríguez-hornedo, D. Murphy, Significance of controlling crystallization
mechanisms and kinetics in pharmaceutical systems, J. Pharm. Sci. 88 (1999)
651–660.
[32] F. Cilurzo, P. Minghetti, A. Casiraghi, L. Tosi, S. Pagani, L. Montanari,
Polymethacrylates as crystallization inhibitors in monolayer transdermal
patches containing ibuprofen, Eur. J. Pharm. Biopharm. 60 (2005) 61–66.
[33] M. Iervolino, B. Cappello, S.L. Raghavan, J. Hadgraft, Penetration enhancement
of ibuprofen from supersaturated solutions through human skin, Int. J. Pharm.
212 (2001) 131–141.
[34] L. Lindfors, S. Forssen, J. Westergren, U. Olsson, Nucleation and crystal growth
in supersaturated solutions of a model drug, J. Colloid Interface Sci. 325 (2008)
404–413.
[35] M.L. Leichtnam, H. Rolland, P. Wuthrich, R.H. Guy, Impact of antinucleants on
transdermal delivery of testosterone from a spray, J. Pharm. Sci. 96 (2007) 84–
92.
[36] H. Zhai, H.I. Maibach, Effects of occlusion: percutaneous absorption, in: R.L.
Bronaugh, H.I. Maibach (Eds.), Percutaneous Absorption: Drugs-Cosmetics-
Mechanisms-Methodology, Taylor & Francis, Boca Raton, 2005, pp. 235–245.
[37] Y.C. Ng, Z. Yang, W.J. McAuley, S. Qi, Stabilisation of amorphous drugs under
high humidity using pharmaceutical thin films, Eur. J. Pharm. Biopharm. 84
(2013) 555–565.
[38] J. Hadgraft, J.d. Plessis, C. Goosen, The selection of non-steroidal anti-
inflammatory agents for dermal delivery, Int. J. Pharm. 207 (2000) 31–37.
